A

$7 billion market valuation and the credibility of the entire field of RNA interference drug development is riding on the results of Alnylam Pharmaceuticals’ (ALNY) next big clinical trial.

No pressure, folks.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X